Description
GLP-2 is NuLumin’s designation for tirzepatide, a synthetic peptide research compound acting as a dual agonist at the GIP and GLP-1 receptors. In laboratory research it is used to study combined incretin signaling.
Preclinical literature describes investigations into glucose balance, insulin secretion, appetite-related behavior, and joint activation of two incretin receptors, carried out using cell-based assays and animal studies. Its dual-target build supports research into receptor cooperation.
Intended use: In vitro and preclinical in vivo laboratory research only. Not approved for human or veterinary use.
Reviews
There are no reviews yet.